DYNAMICS OF CARDIOVASCULAR STATUS AND SERUM MARKERS OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS, TREATED WITH INFLIXIMAB

DYNAMICS OF CARDIOVASCULAR STATUS AND SERUM MARKERS OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS, TREATED WITH INFLIXIMAB

Bibliographic Details
Main Authors:	S. P. Oranskyi, L. N. Eliseeva, N. A. Samorodskaya, I. G. Malkhasyan
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2013-04-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	ревматоидный артрит эндотелиальная дисфункция фактор некроза опухоли-α тканевой активатор плазминогена микроциркуляция интерлейкин-10
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/181

Similar Items

Ihmor necrosis factor-a inhibitors and cardiovascular risk in rheumatoid arthritis
by: Tatiana Valentinovna Popkova, et al.
Published: (2012-12-01)

Endothelial dysfunction in patients with rheumatoid arthritis and comorbidity
by: A. K. Knyazeva, et al.
Published: (2018-01-01)

Factors determining long-term success of biologic therapy in rheumatoid arthritis
by: Dmitry Evgenyevich Karateev
Published: (2015-09-01)

Potential biochemical markers of chronic bronchitis
by: E. A. Kurtukov, et al.
Published: (2021-07-01)

ЭНДОТЕЛИАЛЬНАЯ ДИСФУНКЦИЯ У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ НА ФОНЕ ЛЕЧЕНИЯ МЕТОТРЕКСАТОМ
by: S. M. Mukhammadieva, et al.
Published: (2015-12-01)

RESULTS OF TENEKTEPLASE USE IN MASSIVE PULMONARY THROMBOEMBOLISM. CLINICAL CASE
by: R. Rajan, et al.
Published: (2016-01-01)

Rheumatoid arthritis therapy with genetically engineered biological agents in the Republic of Karelia
by: Irina Mikhailovna Marusenko
Published: (2013-12-01)

An angiotensin-converting enzyme inhibitor in the combination treatment of rheumatoid arthritis
by: E. B. Komarova, et al.
Published: (2017-09-01)

PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS IN THE 21st CENTURY: FOCUS ON RITUXIMAB
by: Evgeni Lvovich Nasonov
Published: (2009-12-01)

The Influence of the Variability of the Profibrinolytic Response of the Blood Vessel Wall on the Effectiveness of Treatment of Primary Open-Angle Glaucoma. Part 3
by: S. I. Makogon, et al.
Published: (2020-06-01)

Endothelial dysfunction and periodontal hemodynamic disturbances in young patients with nicotine dependence
by: A. V. Naumov, et al.
Published: (2012-04-01)

Predicting the efficacy of tofacitinib therapy based on gene expression of proinflammatory cytokines and proteases in cultured blood cells of patients with rheumatoid arthritis
by: G. A. Markova, et al.
Published: (2022-10-01)

Serum concentrations of interleukin-6 and tumor necrosis factor alpha in patients with spondyloarthritis: a relationship between systemic inflammation and anemia
by: К. N. Safarova, et al.
Published: (2022-07-01)

Hemodynamic determinants of physical training effectiveness in rheumatoid arthritis patients
by: A. A. Zavodchikov, et al.
Published: (2007-08-01)

Diagnostic markers in the aspect of the development of HIV-encephalopathy in children
by: S. N. Saidkhodjaeva, et al.
Published: (2021-10-01)

Clinical and immunological characteristics of chronic obstructive pulmonary disease with frequent exacerbations associated with obliterating atherosclerosis of lower limb arteries
by: S. N. Kotlyarov, et al.
Published: (2023-10-01)

Patient stratification and choice of therapy based on blood gene expression profiles in rheumatoid arthritis
by: E. V. Chetina, et al.
Published: (2018-12-01)

The interchangeability of original tumor necrosis factor- α inhibitors and biosimilars in rheumatology: experience in replacing original infliximab with Flammagis for ankylosing spondylitis
by: Yu. V. Muravyev, et al.
Published: (2020-05-01)

INFLIXIMAB (REMICADE): POSSIBILITIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS
by: Nataliya Vladimirovna Chichasova, et al.
Published: (2011-03-01)

THE INVOLVEMENT OF ENDOTHELIAL DYSFUNCTION MARKERS IN THE PATHOGENESIS OF CHRONIC GLOMERULONEPHRITIS
by: T.V. Margieva, et al.
Published: (2006-03-01)

Tumor necrosis factor-? inhibitors in therapy for psoriatic arthritis
by: Vladimir Vasilyevich Badokin, et al.
Published: (2010-12-01)

Role of interleukin-6 in the development of atherosclerosis in rheumatoid arthritis
by: Elena Vasilyevna Udachkina, et al.
Published: (2013-10-01)

Use of methotrexate in the treatment of psoriasis and psoriatic arthritis
by: Tatiana Viktorovna Korotaeva, et al.
Published: (2013-06-01)

EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)
by: E.I. Alexeeva, et al.
Published: (2006-03-01)

Vascular and platelet hemostasis and microcirculation in arterial hypertension patients
by: L. L. Kirichenko, et al.
Published: (2005-08-01)

Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis
by: T. V. Korotaeva, et al.
Published: (2019-05-01)

Perspectives for uveitis treatment in rheumatic diseases
by: Alla Aleksandrovna Godzenko, et al.
Published: (2011-06-01)

Combination of ankylosing spondylitis and rheumatoid arthritis: clinical observations and literature review
by: A. A. Godzenko, et al.
Published: (2021-08-01)

New areas of the pharmacotherapy of rheumatic diseases are inhibition of interleukin-6 and interleukin-17
by: Evgeny Lvovich Nasonov
Published: (2013-10-01)

Features of the subpopulation composition of dendritic cells in patients with rheumatoid arthritis
by: M. A. Korolev, et al.
Published: (2019-09-01)

How real is the long-lasting effect of tumor necrosis factor α inhibitors? Focus on immunogenicity
by: D.E. Karateev
Published: (2014-05-01)

Anti-cyclic citrullinated peptide antibodies – a role in rheumatoid arthritis and the possibility of seroconversion: A focus on abatacept
by: N. V. Chichasova
Published: (2017-03-01)

Golimumab in the treatment of psoriatic arthritis: efficacy and safety
by: Tatiana Viktorovna Korotaeva, et al.
Published: (2015-09-01)

Apoptosis cells and regulation factors in patients with multiple sclerosis
by: S. A. Vostryakova, et al.
Published: (2009-02-01)

Диклофенак устраняет влияние фактора некроза опухоли на систему кровообращения анестезированной крысы
by: Татьяна Сергеевна Туманова, et al.
Published: (2022-08-01)

Диклофенак устраняет влияние фактора некроза опухоли на систему кровообращения анестезированной крысы
by: Татьяна Сергеевна Туманова, et al.
Published: (2022-08-01)

Angiogenesis in patients with psoriasis and psoriatic arthritis: cell-mediated and humoral mechanisms, its role in pathogenesis, and searching for promising therapeutic targets
by: T.V. Korotaeva
Published: (2014-05-01)

Seropositive juvenile rheumatoid arthritis: analysis of the spectrum of clinical manifestations and therapy according to a retrospective study
by: М. I. Kaleda, et al.
Published: (2021-02-01)

CYCLOSPORINE A IN RHEUMATOID ARTHRITIS: CURRENT DATA
by: Elena Lvovna Luchikhina
Published: (2009-09-01)

Efficiency and safety of leflunomide in rheumatoid arthritis: Results of a Russian observational multicenter of trial
by: R. M. Balabanova, et al.
Published: (2015-06-01)